文献速递牙周病

基因型驱动的NPC1L1与PCSK9抑制与牙周炎风险降低相关

Genotype-driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis.
PubMed 文献 · J Clin Periodontol · 2022-09-02

研究利用全基因组关联分析数据,以基因变异代理HMGCR、NPC1L1和PCSK9抑制,检验其与牙周炎的关联。结果发现NPC1L1抑制(OR=0.53)和PCSK9抑制(OR=0.84)与牙周炎风险降低相关,而HMGCR抑制无显著关联。

要点

  • 基因代理的NPC1L1抑制与牙周炎风险降低相关(OR=0.53)。
  • 基因代理的PCSK9抑制与牙周炎风险降低相关(OR=0.84)。
  • 基因代理的HMGCR抑制与牙周炎风险无显著关联(OR=0.92)。

核心结论

  • 基因代理的NPC1L1和PCSK9抑制与牙周炎风险降低相关。

研究设计与样本

  • 利用全基因组关联分析(GWAS)荟萃分析(N=188,578)中与低密度脂蛋白胆固醇相关的HMGCR、NPC1L1和PCSK9基因变异,代理相应药物的治疗性抑制。
  • 牙周炎关联数据来自GeneLifestyle Interactions in Dental Endpoints联盟的GWAS,包含17,353例病例和28,210例对照。
  • 采用广义加权最小二乘分析校正基因型连锁不平衡,得出汇总估计值。

主要发现

  • 基因代理的HMGCR抑制(相当于LDL降低1 mmol/L)与牙周炎风险无显著关联(OR=0.92,95%CI:0.73;1.16;p=.4905;FDR=0.4905)。
  • 基因代理的NPC1L1抑制与牙周炎风险降低相关(OR=0.53,95%CI:0.35;0.81;p=.0038;FDR=.0077)。
  • 基因代理的PCSK9抑制与牙周炎风险降低相关(OR=0.84,95%CI:0.74;0.95;p=.0051;FDR=.0077)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Epidemiological and pre-clinical studies suggest a chemoprotective role of lipid-lowering agents in periodontitis. We tested the association of genetically proxied inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), Niemann-Pick C1-Like 1 (NPC1L1) and proprotein convertase subtilisin/kexin type 9 (PCSK9) with periodontitis. MATERIALS AND METHODS: Genetic variants in HMGCR, NCP1L1 and PCSK9 associated with low-density lipoprotein (LDL) cholesterol in a genome-wide association study (GWAS) meta-analysis (N = 188,578) were used to proxy therapeutic inhibition of HMGCR, NPC1L1 and PCSK9. For these genetic variants, associations with periodontitis were obtained from GWAS of 17,353 cases and 28,210 controls in the GeneLifestyle Interactions in Dental Endpoints consortium. Generalized weighted least squares analysis accounted for linkage disequilibrium of genotypes to derive pooled estimates. RESULTS: While genetically proxied HMGCR inhibition equivalent to 1 mmol/L reduction in LDL was not associated with odds of periodontitis (odds ratio [OR] = 0.92 [95% confidence interval [CI]: 0.73; 1.16]; p = .4905; false discovery rate [FDR] = 0.4905), genetically proxied NPC1L1 (OR = 0.53 [95% CI: 0.35; 0.81]; p = .0038; FDR = 0.0077) and PCSK9 (OR = 0.84 [95% CI: 0.74; 0.95]; p = .0051; FDR = 0.0077) inhibition lowered the odds of periodontitis. CONCLUSIONS: Genetically proxied inhibition of NCP1L1 and PCSK9 was associated with lower odds of periodontitis.

来源:J Clin Periodontol,查看原文。版权归原作者所有。

引用

  1. Baumeister SE, Holtfreter B, Reckelkamm SL, et al. Genotype-driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis. J Clin Periodontol. 2022. PMID: 36054135. doi:10.1111/jcpe.13719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。